Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

irmed

Evotec confirms its financial targets for the year 2007. Revenues for the continuing operations are expected to be in the range of EUR 30 - 35 million. The sale of the Chemical Development business to Aptuit Inc. will contribute a non-operating profit of approximately GBP 17 million (approx. EUR 25 million) in Q4 2007 subject to the final closing of the books. Including the cash proceeds from this transaction, the targeted year-end cash position improves significantly to between EUR 93 million and EUR 98 million.

Conference Call

Evotec will hold a conference call today at 02.00 p.m. CET (01.00 p.m. GMT/08.00 a.m. US time East Coast) to discuss the financial results as well as progress in first nine months of 2007. Jorn Aldag, President & CEO, Dr Klaus Maleck, Chief Financial Officer, and Dr John Kemp, Chief Research & Development Officer, will lead the call.

Conference Call Numbers (listen only):

Europe: +49(0)69-5007-1308 (Germany)

+44(0)20-7806-1955 (UK)

US: +1-718-354-1389

Access Code: 4882161

Webcast: http://www.evotec.com

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49(0)69-22222-0418 (Germany) or +44(0)20-7806-1970 (UK) and in the US by +1-718-354-1112. The access code is 4882161#. The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Financial Reports.

Forward Looking Statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business combin
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
(Date:12/24/2014)... The report expects global cell isolation and ... provides a carefully analyzed data about the vital drivers, restraints, ... Copy of Report @ http://bit.ly/1yUxy0T , According to ... witnessing growth at an impressive CAGR during near future. It ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Wis. - As law professors at major universities, Rebecca ... case perfectly clear: they are not calling for repeal of ... patent their inventions. They are advocating an adjustment that ... University of Michigan and Rai of Duke University ...
... - An agreement struck to accelerate the transformation of ... visions of a medical discovery triangle connecting Milwaukee, Madison, ... milestone in the drive to facilitate scientific collaboration and ... formally joined forces with WiSys Technology Foundation, Inc. ...
... Madison, Wis. - Quick quiz: Which Wisconsin institutions spend ... , ,Naming No. 1 is relatively easy: the University ... academic R&D centers in the United States. Second on the ... million), which ranks among the nation's top 100 medical research ...
Cached Biology Technology:Professors want to tweak, not overhaul, patent law 2Professors want to tweak, not overhaul, patent law 3WiSys to patent Marshfield Clinic discoveries 2Marshfield Clinic and UW combine to speed tech growth 2Marshfield Clinic and UW combine to speed tech growth 3Marshfield Clinic and UW combine to speed tech growth 4
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... The Federation of American Societies for Experimental Biology ... Science Research Conference (SRC): Matricellular Proteins in Development, ... their surrounding extracellular matrix (ECM) are the basis ... tissue organization in all metazoan organisms. Structural ECM ...
... Federation of American Societies for Experimental Biology (FASEB) ... Research Conference (SRC): Hematologic Malignancies. The 2013 ... and unique scientific conference where basic and translational ... in detail in the premier meeting in the ...
... University published a paper in Nature , concluding that ... of Mendelian inheritance (the idea that all genes are inherited ... demonstrating genetic traits from older generations, which shouldn,t be possible ... on. At the time of publishing, the paper ...
Cached Biology News:FASEB SRC announces conference: Matricellular Proteins in Development, Health, and Disease 2Defying the laws of Mendelian inheritance 2
... Cellomics KineticScan™ Reader is Cellomics‘ ... Solutions for Cell-based Screening". The ... ability to do both temporal ... physiological processes, dynamic distribution and ...
... may be superior to transfection in some ... with PULSin you can study lethal proteins ... of proteins in cells. Likewise, delivery of ... traditional RNA interference experiments. ,With PULSin ...
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
... ST-195 allows real-time observations of cell cultures ... has 64 different strain parameters in addition ... thin silicon strain chamber used by the ... fluorescence microscopy. ST-195 can be used with ...
Biology Products: